IMCCNasdaqMedicinal Chemicals & Botanical ProductsFiscal year ends December 31

IM Cannabis Corp.

Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 30, 2026

$1.50+0.11 (+7.91%)

Close on Oct 19, 2026

Debt

Borrowings on the balance sheet, Dec 31, 2025

Total debt

C$16.21M

C$15.27M due within a year

Net debt

C$13.48M

After C$2.73M of cash

Implied interest rate

21.70%

FY2025 interest ÷ average debt

Interest coverage

-3.3×

FY2025 operating income ÷ interest

Total debt by fiscal year

Long-term plus current debt, CAD

Bond issues

Individual notes and bonds outstanding

Bond-level data is not connected yet

Coupon, maturity and amount of each note will come from the debt footnote in IM Cannabis's annual report. Trading prices and yields need FINRA TRACE data.

Where these numbers come from

Parsed from the XBRL in IM Cannabis's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-30 reverse split on Aug 27, 2026
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is IMCC.

Revenue growth1.3% · median 22.1%

Gross margin17.7% · median 35.5%

Operating margin-21.2% · median -28.1%

Net margin-20.7% · median -20.1%

Company	Revenue	Growth
CGC	C$293.63M	+6.8%
CRON	$179.09M	+37.5%
IMCC	C$54.73M	+1.3%
ACB	–	–
CWLXF	–	–
GLAS	–	–

Company

Exchange: Nasdaq
Industry: Medicinal Chemicals & Botanical Products
Fiscal year ends: December 31
Employees: 95
Auditor: KOST FORER GABBAY & KASIERER
SEC CIK: 1792030

Advertisement
300 × 250